Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy

Oncology Reports

Volumn 9, Issue 3, 2002, Pages 627-630

  Steins, Martin B ^a   Serve, Hubert ^a   Zühlsdorf, Michael ^a   Senninger, Norbert ^a   Semik, Michael ^a   Berdel, Wolfgang E ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Carboplatin etoposide; Ifosfamide doxorubicin; Malignant peripheral nerve tumour; Malignant schwannoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE;

ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESISTANCE; FEMALE; HUMAN; MALE; METASTASIS; MIDDLE AGED; NEURILEMOMA; PATHOLOGY; SOFT TISSUE TUMOR; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEURILEMMOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0036584921     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.3.627     Document Type: Article

References (26)

1. Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G and DeConti RC: A comparison of adriamycin versus vincristine and adriamycin, cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50: 2757-2762, 1982. (Pubitemid 13220781)
2. Wilson RE, Wood WC, Lerner HL, Antman K, Amato D, Corson JM, Proppe K, Harmon D, Carey R, Greenberger J, et al: Doxorubicin chemotherapy in the treatment of soft-tissue sarcoma. Combined results of two randomized trials. Arch Surg 121: 1354-1359, 1986. (Pubitemid 17180527)
3. Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, Wilimas JA, Hayes FA and Green AA: Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 71: 131-135, 1987. (Pubitemid 17030141)
4. Nielson OS, Judson I, van Hoesel Q, Le Cesne A, Keizer HJ, Blay JY, van Oosterom A, Radford JA, Svancarova L, Krzemienlecki K, Hermans C, van Glabbeke M, Oosterhuis JW and Verweij J: Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 36: 61-67, 2000. (Pubitemid 30035345)
5. Schuette J, Mouridsen HT, Steward W, Santoro A, van Oosterom AT, Somers R, Blockledge G, Verweij J, Dombernowsky P, Thomas D, et al: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 26: 558-561, 1990. (Pubitemid 20259327)
6. Chevallier B, Leyvraz S, Olivier JP, Fargeot P, Facchini T and Vo Van ML: Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. Cancer Invest 11: 135-139, 1993. (Pubitemid 23105029)
7. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E, et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11: 15-21, 1993. (Pubitemid 23059969)
8. Le Cesne A, Judson I, Crowther D, Rodenhuis S, Keizer HJ, van Hoesel Q, Blay JY, Frisch J, van Glabbeke M, Hermans C, van Oosterom A, Tursz T and Verweij J: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18: 2676-2684, 2000. (Pubitemid 30463549)
9. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S and Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against soft tissue sarcomas. J Clin Oncol 11: 1269-1275, 1993. (Pubitemid 23199129)
10. Elias A, Ryan L, Sulkes A, Collins J, Aisner J and Antman KH: Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 7: 1208-1216, 1989. (Pubitemid 19220122)
11. Bokemeyer C, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Schoffski P and Poliwoda H: Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. Ann Oncol 3: 487-488, 1992.
12. Casali P, Pastorino U, Zucchinelli P, Devizzi L, Azzarelli A, Quagliuolo V, Bignami P, Santoro A and Bonadonna G: Epirubicin plus ifosfamide and dacarbazine (EID) in advanced tissue sarcomas. Ann Oncol 3 (Suppl. 2): S125-S126, 1992.
13. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, et al: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537-1545, 1995.
14. O'Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S and Wittes RE: Etoposide (VP-16-213). Current status of an active anticancer drug. N Engl J Med 312: 692-700, 1985. (Pubitemid 15134707)
15. Dombernowsky P, Buesa J, Pinedo HM, Santoro A, Mouridsen H, Somers R, Bramwell V, Onsrud M, Rouesse J, Thomas D, et al: VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer Clin Oncol 23: 579-580, 1987. (Pubitemid 17057392)
16. Licht JD, Mazanet R, Loehrer PJ, Gonin R and Antman KH: Phase IV trial of daily oral etoposide in the treatment of advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 34: 79-80, 1994. (Pubitemid 24194564)
17. Edmonson JH, Buckner JC, Long HJ, Loprinzi CL and Schaid DJ: Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst 81: 863-866, 1989. (Pubitemid 19147391)
18. Saeter G, Alvegard TA, Monge OR, Strander H, Turesson I, Klepp R, Soderberg M, Wist E, Raabe N, Erlanson M, Solheim OP and Hannisdal E: Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. Eur J Cancer 33: 1551-1558, 1997. (Pubitemid 28123474)
19. Phillips MB and Pinkerton CR: Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas. Eur J Cancer 28: 399-403, 1992.
20. Winkler K, Bielack SS, Delling G, Jügens H, Kotz R and Salzer-Kuntschik M: Treatment of osteosarcoma: experience of the cooperative osteosarcoma study group (COSS). Cancer Treat Res 62: 269-277, 1993.
21. Papai Z, Bodoky G, Szanto J, Poller I, Rahoty P, Eckhardt S, Lang I and Szendroi M: The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer 89: 177-180, 2000. (Pubitemid 30451288)
22. Goldstein D, Cheuvart B, Trump DL, Shiraki M, Comis RL, Tormey DC, Harris JE and Borden EC: Phase II trial of carboplatin in soft-tissue sarcoma. Am J Clin Oncol 13: 420-423, 1990. (Pubitemid 20344519)
23. Klingebiel T, Pertl U, Hess CF, Jügens H, Koscielniak E, Pötter R, van Heek-Romanowski R, Rossi R, Schött C, Spaar HJ, Willnow U and Treuner J: Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol 30: 269-275, 1998. (Pubitemid 28175622)
24. Pastorino U: Metastasectomy for soft tissue sarcomas. Cancer Treat Res 91: 65-75, 1997.
25. Van Geel AN, Pastorino U, Jauch KW, Judson IR, van Coevorden F, Buesa JM, Nielson OS, Boudinet A, Tursz T and Schmitz PI: Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 77: 675-682, 1996. (Pubitemid 26055392)
26. Van Oosterom AT and Verweij J: New drugs for the treatment of sarcomas. Hematol Oncol Clin North Am 9: 909-925, 1995.